Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fexuprazan on Atorvastatin Pharmacokinetics in Healthy Subjects
NCT05812404Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD), sponsored by Daewoong Pharmaceutical. Primary endpoints: Atorvastatin Peak Plasma Concentration at steady state up to 64 days and Atorvastatin Area under the plasma concentration versus time curve at steady state up to 64 days. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05812404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812404.